CJC-1295 with DAC kept hormone readings higher for days
In the DAC study, blood hormone levels stayed higher for days. I want to give that finding its due while leaving the question of feeling better open.
A rectangular hinge holds turquoise steel beside pale concrete, with water just below the joint.
It copies a releasing signal
GHRH means growth hormone-releasing hormone. An analog is a substance that resembles it. CJC-1295 encourages release; it isn’t growth hormone itself.
The signal goes to the pituitary gland, which releases growth hormone. DAC is an extra attachment found in some preparations. It binds the peptide to a blood protein called albumin, helping it stay around longer.
The FDA separates the attached form from CJC-1295 without DAC. They are different active ingredients. Evidence about one form doesn’t automatically apply to a different preparation.
The days-long finding belongs to the DAC form. The shorter name leaves that important detail out.
What lasted for days?
The study measured blood hormones in healthy adults. Those results tell us about a response, without showing better sleep, strength or recovery.
In the CJC-1295 DAC study in healthy adults, average growth hormone levels stayed higher for at least six days after a single injection. Average levels of the related growth factor IGF-1 stayed raised for nine to eleven days.
But the study didn’t establish an improvement in how people felt or functioned. A longer hormone response and a longer benefit are different things. Only the first was shown here.
A separate CJC-1295 DAC study in healthy men found continuing hormone pulses. The low level between pulses also rose. So “it keeps the pulses” leaves out part of the change in exposure.
The peaks can keep arriving while the low points rise. Both are part of the result.
The risks need room too
A lasting response doesn’t come with a settled safety answer. The studies were small, and longer-term safety in people is unknown.
The FDA’s review describes injection-site reactions, headaches and flushing. A faster heartbeat and blood-vessel widening are also on FDA’s list of concerns. These deserve a place beside the hormone results.
FDA also raises concerns about blood sugar and fluid retention because of the effects of elevated growth hormone. These are potential risks, rather than measured long-term rates for CJC-1295.
CJC-1295 has no FDA-approved use. These experiments don’t give a personal treatment plan or an injection schedule. The questions page keeps the distinction between releasing a hormone and helping a person in view.